Lundbeck Gets Dibs on Proximagen CNS Products
By Catherine Shaffer
Friday, September 30, 2011
Proximagen Group plc, of London, partnered three of its developmental central nervous system (CNS) programs with H. Lundbeck A/S, of Valby, Denmark, in exchange for a stock purchase worth £10.3 million (US$16.2 million). The companies will work together to develop the three programs in the areas of epilepsy, pain and inflammatory disorders.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.